LivFul

What LivFul does

LivFul Inc. is a Texas-incorporated, private biotechnology company that develops therapeutic and preventive health products for underserved populations in the global south, spanning Africa, Asia, and Latin America. The company's product portfolio comprises three core assets: STAYTEC™, a patented, non-toxic aromatic insect repellent offering 14 hours of protection and a reported 100% reduction in malaria cases; LV101R Tablet, a treatment for gastrointestinal and colorectal cancers currently in clinical trials in Brazil; and LV201R Tablet, a preclinical candidate for glioblastoma with demonstrated anti-tumor activity in mouse and chicken membrane models. The underlying technology is grounded in proprietary chemistry — novel aromatic repellent compounds and small-molecule therapeutics — rather than platform software or AI-driven discovery.

LivFul operates a three-stage business model branded as L.I.F.E. (Liberating Innovation For Everyone): acquiring overlooked pharmaceutical IP, de-risking it through early-stage clinical validation in partnership with local health systems in developing countries at lower cost than US-equivalent trials, and distributing through a dual-track channel. Revenue is intended to come from out-licensing approved products to global north pharmaceutical partners and from direct distribution via public/private partnerships in the global south. No revenue has been disclosed to date. The company is led by Co-CEOs Hogan Bassey (Founder) and Matt Elsberry, with divisional CEOs for Therapeutics and Global Health, a Chairman (Yaw Nsarkoh), and functional C-suite including CFO, COO, CSO, and Global Director of R&D.

Name

LivFul

Legal name

LivFul Inc.

Website

https://livful.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

LivFul is a private biotech company developing patented therapeutics and preventive health products — including the STAYTEC™ insect repellent and cancer drug candidates LV101R and LV201R — for underserved populations in the global south across Africa, Asia, and Latin America.

Ownership category

akta.pro rank

Product category

Pharmaceuticals & Biotechnology

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Mosquito Control Products (Larvicides, Dunks, Foggers) (CRAJAHAI)

akta.pro secondary industries

Insect & Pest Control (Indoor/Outdoor Insecticides, Repellents, Traps) (CRADAKAJ), Compounding Ingredient & API Distributors (Pharma Supply) (HLAIAJAO)

Keywords

• Pharmaceutical development
• Insect repellent technology
• Cancer therapeutics
• Malaria prevention products
• Global health equity

Headquarters

HQ city

Alpharetta

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

1. Product Licensing: Out-licensing of developed products to global north pharmaceutical partners after obtaining regulatory approval.
2. Product Distribution: Direct distribution of health products in the global south through public/private partnerships.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels1 record

Core offering

LivFul develops and commercializes pharmaceutical products for underserved populations in the global south. Its portfolio includes STAYTEC™, a patented non-toxic aromatic insect repellent offering 14 hours of protection against malaria and other mosquito-borne diseases, and two cancer therapeutic tablets (LV101R for gastrointestinal/colorectal cancers and LV201R for glioblastoma). The company out-licenses developed products to global north pharmaceutical partners and distributes through public/private partnerships in developing countries across Africa, Asia, and Latin America.

Product overview

LivFul is a pharmaceutical company developing transformative health solutions for underserved populations in the global south. The product portfolio consists of three core therapeutic candidates: STAYTEC™ is a next-generation insect repellent targeting malaria prevention; LV101R Tablet addresses gastrointestinal and colorectal cancers; and LV201R Tablet focuses on glioblastoma treatment. The company operates a three-stage model: discovering overlooked pharmaceutical IP, developing early clinical validation through partnerships with local health systems, and distributing equitably via global pharmaceutical partnerships and public/private distribution networks.

Differentiator

Problem solved

Functional benefit

Brands

• STAYTEC: A next-gen, life-saving insect repellent that offers 14 hours of protection and 100% reduction in malaria cases. Patented, non-toxic, aromatic repellent protecting from malaria and other mosquito-borne diseases.
• L.I.F.E.

Products and services

• STAYTEC™ A next-generation, patented, non-toxic aromatic insect repellent offering 14 hours of protection from malaria and other mosquito-borne diseases, with 98% mosquito landing reduction and 100% reduction in malaria cases. Designed for underserved populations in developing countries.
• LV101R Tablet A therapeutic tablet in clinical development as a safe treatment for gastrointestinal and colorectal cancers, with potential for broad-spectrum cancer therapy. Currently in clinical trials in Brazil.
• LV201R Tablet A therapeutic tablet in preclinical development as a novel, safe treatment for glioblastoma with potential to replace chemotherapy and serve as broad-spectrum cancer therapy. Preclinical data show suppressed tumor growth and reduced volume in mouse model, anti-tumor and anti-angiogenic activity in chicken membrane, and promoted apoptosis in numerous cancer cell lines.

Quantifiable outcome

• 98% reduction in mosquito landings
• +5 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• Local Health Systems (Developing Countries)coreStrategic or Co-development PartnerPartnerships with local health systems across developing countries to de-risk drug programs through early-stage, small-scale human efficacy trials at lower costs and to US FDA standards.
• Global North Pharmaceutical PartnerscoreChannel Partner/ Reseller/ DistributorOut-licensing partnerships with global pharmaceutical companies for distribution of LivFul-developed products after regulatory approval.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Johnson & Johnson: J&J operates both a global consumer health business and a major pharmaceutical oncology pipeline, and runs global health access programs for underserved populations. Comparable to LivFul as a large incumbent that could serve as a global north licensing partner for either the repellent or oncology assets.
• SC Johnson: SC Johnson owns major consumer insecticide and repellent brands including OFF!, Raid, and Autan. It is a broad incumbent in the same insect repellent category as STAYTEC, with established global distribution and R&D capabilities that a successful out-licensing by LivFul could leverage.
• GSK (Global Health and Vaccines): GSK operates a major Global Health business focused on infectious diseases in developing countries and is also an oncology therapeutics developer. Comparable to LivFul as both a potential out-licensing partner for global south products and a broad incumbent in pharmaceutical R&D targeting underserved diseases.
• Bayer (Consumer Health and Pharma): Bayer's Consumer Health division markets insect repellents (e.g., Autan) and the company also has a major pharmaceutical pipeline including oncology. It overlaps with LivFul across both core product lines (repellent and cancer therapeutics) and is a plausible out-licensing counterparty.
• Sumitomo Chemical (Vector Control division): Sumitomo Chemical produces Olyset Plus long-lasting insecticidal nets for malaria control through its vector control division, in partnership with the WHO. Comparable to LivFul's STAYTEC as a science-driven malaria prevention product sold into developing country health systems and global health funding channels.
• BASF: BASF supplies active ingredients and formulation technologies used in insect repellent products globally, including IR3535. As a chemistry-driven incumbent in the repellent supply chain, it is comparable to LivFul on the underlying technology platform of STAYTEC and represents both a competitor and potential licensing partner.

Direct peers

• Sawyer Products: Sawyer Products manufactures topical insect repellents, including permethrin-based and DEET alternatives, marketed to outdoor and global health consumers. It directly competes with STAYTEC in the consumer repellent category and serves a similar use case for mosquito-borne disease prevention.
• Vestergaard: Vestergaard manufactures PermaNet long-lasting insecticidal nets and other vector-control products for malaria prevention in developing countries. It is the most direct comparable to LivFul's STAYTEC repellent given its mission-aligned, malaria-focused product portfolio and global south distribution model.

Emerging players

• Medicines for Malaria Venture (MMV): MMV is a product development partnership focused on discovering, developing, and delivering new antimalarial drugs. While not a commercial peer, it is closely comparable to LivFul's L.I.F.E. model of sourcing overlooked IP and advancing it for global south populations, and could be a partner or funder.
• Sarepta Therapeutics: Sarepta is a clinical-stage biotech developing novel therapeutics for serious diseases, including oncology-adjacent indications, with an out-licensing and partnership-driven model. Comparable to LivFul as a small-cap biotech pursuing breakthrough therapeutics via specialized clinical development rather than fully integrated commercialization.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/livfulinc

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds6 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LivFul